BioSpace News Archive

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2020.

Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, reported financial results for the third quarter ended September 30, 2020 and provided business highlights.

CV Sciences, Inc., a preeminent supplier and manufacturer of hemp cannabidiol products, announced its financial results for the quarter ended September 30, 2020.

Rigel Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2020, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Luminex Corporation announced results for its third quarter ended September 30, 2020.

Avidity Biosciences, Inc. announced that Sarah Boyce, President and Chief Executive Officer, will be presenting at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on Thursday, November 12th, 2020 at 8:45am PST.

Cardiff Oncology, Inc., a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, announced company highlights and financial results for the third quarter ended September 30, 2020.

Landmark data supporting universal genetic testing in cancer and the utility of germline and somatic testing to improve patient management published

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will host a conference call and webcast on Thursday, November 12, 2020 at 5:00 p.m. to discuss financial results and corporate developments for the third quarter ended September 30, 2020.

Marketing Authorisation Application for QINLOCK in Fourth-line GIST Validated by the European Medicines Agency; Commercial Planning for Europe Underway